Free Pediatrics CME

  • FREE

    The Current and Emerging Landscape of Pharmacotherapy for Neonatal Respiratory Distress Syndrome (NRDS)

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Neonatal respiratory distress syndrome (RDS) occurs in 10.1% of preterm infants born at 34 weeks’ gestational age (GA), corresponding to an over 40-fold increased risk as compared to their 39- to 40-week-GA counterparts. The risk decreases with increasing GA; at a GA of 37 weeks, the risk has fallen to just to just three times that of a full-term infants. Aside from premature birth, risk factors include: maternal gestational diabetes, male infant, and multiplets.

    Target Audience:

    The following healthcare professionals: neonatologists; physician assistants, nurse practitioners, nurses, and pharmacists who clinically encounter neonatal patients with RSD.

    By the end of the session the participant will be able to:

    • Identify the pathophysiology, clinical features, and strategies for diagnosis of neonatal RDS
    • Review current and emerging options for the management of neonatal RDS
    • Develop pre- and postnatal treatment plans for the prevention and management of neonatal RDS
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 12/5/2020
    • Expiration of CME credit: 12/5/2022
  • FREE

    Cystic fibrosis: Therapeutic updates and optimizing treatment

    Cystic Fibrosis (CF) is a genetic disease that affects nearly 70,000 people worldwide with more than 90% of patients diagnosed of Caucasian descent and a median lifetime survival remains a mere 43.6 years. CF is caused by an autosomal recessive mutation in the CF transmembrane regulator (CFTR) gene, which controls the other chloride and sodium channels at the cell surface and is found in the lungs, liver, pancreas, intestine, sweat duct, and epididymis. The primary organs in which the disease manifests clinically are the pancreas, leading to malabsorption of nutrients, and the lungs due to the accumulation of thick, sticky mucous that contributes to airway obstruction. CF causes several clinical complications, including recurrent pulmonary infections, nasal polyps, CF-related diabetes, fat-soluble vitamin deficiencies, acid reflux, and liver failure.

    Target Audience:

    The following HCPs: pulmonologists, pediatricians, gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with CF.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of CF such that it might inform treatment mechanisms.
    • Identify the currently available and emerging pharmacotherapeutic treatments for the management of CF and apply them to patient cases using evidence-based medicine.
    • Describe newly approved and investigational therapies in development for CF.
    • Evaluate an ongoing treatment plan for a specific patient with CF to optimize safety and efficacy, suggesting modifications for improvement, including the management of complications.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/18/2020
    • Expiration of CME credit: 07/18/2022
  • FREE

    Hemophilia B: Optimizing Pharmacotherapeutic Management Strategies

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same in all geographic regions, populations, and ethnic groups,affecting approximately 1 out of every 30,000 male births. The condition is diagnosed by measuring FIX activity, and patients with severe hemophilia have levels of 1% or less.

    Patients with severe hemophilia B are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years,and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

    Physical therapy can ease symptoms if internal bleeding has damaged a patient’s joints, and surgery may be necessary if internal bleeding has caused severe damage. However, the current standard of therapy for hemophilia B is intravenous infusion of therapeutic factor concentrates. Through the reduction in the number of bleeding incidences and improvement in quality of life, factor replacement therapy has significantly reduced the morbidity and mortality of hemophilia. Furthermore, prophylactic therapy has the demonstrated benefit of reducing the development of hemophilic arthropathy.

    Target Audience:

    The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia B.

    By the end of the session the participant will be able to:

    • Describe the risk factors and occurrence of hemophilia B.
    • Identify available prophylactic and treatment options for hemophilia B and apply them to a patient case.
    • Identify the new treatment options for hemophilia B.
    • Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia B.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/10/2020
    • Expiration of CME credit: 06/10/2022
  • FREE

    Hemophilia A: Optimizing Pharmacotherapeutic Management Strategies

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia A, a mutation in the gene for factor VIII (FVIII) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia A is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 5000 male births. The condition is diagnosed by measuring FVIII activity, and patients with severe hemophilia have FVIII activity of 1% or less. Patients with severe hemophilia A are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

    Target Audience:

    The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia A.

    By the end of the session the participant will be able to:

    • Describe the risk factors and occurrence of hemophilia A.
    • Identify available prophylactic and treatment options for hemophilia A and apply them to a patient case.
    • Identify the new treatment options for hemophilia A.
    • Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia A.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/06/2020
    • Expiration of CME credit: 06/06/2022
  • FREE

    Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma

    Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma consists of two presentations with discussion: Optimal Nursing Strategies to Manage Pediatric Patients with High-Risk Neuroblastoma and Recurrent/Refractory Disease of Pediatric Neuroblastoma: Enhancing the Role of the Nurse.

    At the conclusion of Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you will be able to:
    • Review the fundamentals of diagnosing, treating, and managing high-risk pediatric neuroblastoma
    • Examine strategies to improve supportive care for children with high-risk neuroblastoma
    • Examine the aspects of parental decision-making regarding appropriate care for children with recurrent/refractory neuroblastoma
    • Plan strategies to improve the dialogue and working relationship with parents/caregivers of pediatric patients regarding the goals of care through the treatment continuum and beyond

    Nursing Educational Objective:
    After completing Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you should be able to:
    • Provide appropriate care and counsel for patients and their families

    Target Audiences:
    This program is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: Postgraduate Institute for Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: September 29, 2017
    • Expiration of CME credit: September 29, 2018
  • FREE

    CME: Gaucher disease: Updates from recent research findings

    Gaucher disease (GD) is characterized by a deficiency of the lysosomal enzyme glucocerebrosidase, resulting in the accumulation of sphingolipids throughout the body but most manifesting prominently in the bones. GD is subcategorized based on clinical features: type 1 GD is the non-neuronopathic form and affects mainly the inner organs, while types 2 and 3 are the acute and sub-acute neuropathic forms, whose pathology manifests predominantly within central nervous system. GD impacts about 1 in 75,000 births, making it one of the most common lysosomal storage diseases. One of the first of GD’s complications is the chronic anemia and a persistent bleeding risk. Another is the hepatosplenomegaly, which may be a part of the initial clinical presentation, as may the anatomical abnormalities of bone deformities and stunted growth.

    By the end of the session the participant will be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Gaucher disease including updated recently presented material
    • Describe principles and problems regarding screening for and diagnosing Gaucher disease that can applied to patient cases
    • Describe emerging therapies for Gaucher disease based on research recently presented
    • Design and implement appropriate therapeutic plans for treatment of Gaucher disease based on research recently presented

    Target Audience:

    The following healthcare professionals: pediatricians, neurologists, endocrinologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Gaucher disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 4/28/19
    • Expiration of CME credit: 4/28/21
  • FREE

    Child and adolescent Crohn’s disease: updates in medical and nutritional strategies

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that is defined by a transmural process that often occurs in the terminal ileum but may occur in any portion of the GI tract. Although the exact etiology of CD is unknown, a handful of genetic, immunological, and environmental risk factors have been identified, including an impaired immune response to commensal or pathogenic intestinal microbiota that drives mucosal inflammation in patients who are genetically susceptible.

    Intestinal and abdominal complications such as strictures, abscesses, and fistulas are common among pediatric patients and increase as the disease progresses. Vitamin and mineral deficiencies have also been attributed to IBD due to mucosal inflammation in the gut, low oral intake, and malnutrition resulting in complications such as poor bone health, delayed puberty, anemia, and stunted growth. The annual direct healthcare costs – accounting for the majority of costs in the U.S. – are about $18,000 to $19,000 per patient. CD shares a number of clinical characteristics with other disease states, and initial misdiagnosis and delayed diagnosis of pCD are not uncommon, which may have a dramatic impact on a patient’s clinical course because pCD is often more severe and associated with a higher incidence of complications than adult CD.

    This learning activity has been designed to bring healthcare professionals’ knowledge of the strategies to manage pCD up to date and to improve their competence and performance in treating it.

    Target Audience:

    The following healthcare professionals: pediatricians, pediatric gastroenterologists, and those who specialize in adolescent medicine; physician assistants, nurse practitioners, and pharmacists; and any other healthcare professionals with an interest in or who clinically encounter patients with pCD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Material last updated: September 11, 2021
    • Expiration of CME credit: September 11, 2023